NCT00600366View on ClinicalTrials.gov

Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

January 31, 2005

Study Completion Date

January 31, 2005

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart

Trial Locations (4)

11000

Novo Nordisk Investigational Site, Belgrade

18000

Novo Nordisk Investigational Site, Nis

21000

Novo Nordisk Investigational Site, Novi Sad

34000

Novo Nordisk Investigational Site, Kragujevac

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY